MORE►
Caris
Left: Milan Radovich, SVP and Chief Scientific Officer at Caris Life Sciences; Right: Boris L. Zaïtra, Head of Roche Corporate Business Development [Photos: LinkedIn/Roche]
North Texas’ Caris Life Sciences To Collaborate With Genentech on Novel Therapeutic Targets for Cancers
by Sandra Engelland | Dec 17, 2025
Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25 million and is also eligible for up to $1.1 billion of potential research, development, commercial, and net sales payments, as well as potential tiered royalties on net sales of collaboration therapies, the company said.
by Alex Edwards |
May 12, 2021
Now valued at more than $7.8 billion, Caris specializes in AI-powered genetic sequencing for personalized cancer treatments. The massive capital raise follows a $310 million round in October and boosts the 13-year-old company's total funding to about $1.3 billion.
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
by Alex Edwards |
Aug 20, 2019
The Caris Life Sciences Corporate Park in Irving will increase R&D capabilities with a state-of-the-art precision medicine laboratory, create more than 500 jobs in the region, and help Caris continue to "reinvent cancer care."
MORE►
